Skip to content
FoodEdge
News

Zya Series A: EUR 13.8M (GBP 11.5M) for a 30% sugar-to-fibre claim

Companies House filings confirm the round closed in December 2025. Safety data are peer-reviewed; the 30% conversion claim is still the company's own.

For Startups
AI-generated illustration of a plain square of dark chocolate, a broken biscuit and a small vial of white powder beside a laboratory scale.
Illustration: AI-generated for FoodEdge.

UK start-up Zya has raised a €13.8M (GBP 11.5M) Series A led by Astanor, AgFunderNews reported on 16 November 2026. Filings at Companies House back the figure: Zya Enzymes Ltd allotted Series A-2 shares for about GBP 11.5M in cash between 22 and 30 December 2025. The money was in the bank almost 11 months before the announcement.

The same filings show a further 4.39 million Series A-1 shares allotted on 22 December 2025 at a price about 20% lower, worth about €2.7M (GBP 2.2M). The filings do not say whether that is new money or converted earlier funding. Other reports differ on the headline: Startupmag gives GBP 11.3M and the Soapbox announcement, which carries quotes from Zya and Astanor, gives GBP 12M.

Ahren Innovation Capital, Red Bull Ventures, Zubi Capital, Phase Change and Meach Cove Capital joined the round. Astanor partner Christina Ulardic and Joanna Green of Ahren joined the board on 5 December 2025, according to Companies House. WIRED reported in February 2024 that Zya had raised €4.9M (GBP 4.1M) over two earlier rounds and was aiming for a US launch in 2026. The target is now the end of 2027.

The product is Convero, an inulosucrase enzyme made by precision fermentation in yeast and sold as a dry powder. Zya claims it converts around 30% of the sucrose in a food into fructooligosaccharides (FOS), a prebiotic fibre, once the food dissolves in the stomach. Every report of the 30% figure traces back to the company. Moisture switches the enzyme on, so the first targets are low-moisture foods such as chocolate, cereal bars and biscuits, and heat during processing can inactivate it.

The independent evidence so far covers safety. A peer-reviewed paper in Toxicology Reports (July 2026), co-authored by Zya, found no genotoxicity and no adverse effects in rats at up to 2,000 mg per kg body weight a day for 28 days. Efficacy is less advanced: Zya cites in vitro gut models and preliminary pig studies, and FoodEdge found no published efficacy data. In 2024 Zya told WIRED that pig samples showed meaningful conversion but that it was still quantifying it. Zya's core patent application, WO2022096864, dates from November 2020; the US version is still pending.

The label is the commercial test. Declared sugar on the pack stays the same, and Zya says it will not make calorie or blood glucose claims until it has more data. In the EU, health claims need prior authorisation after an EFSA assessment, which relies mainly on human studies.

What to check

  • Where was the 30% measured: in a gut model, in pigs, or in a finished, heat-processed product?
  • Why did 11 months pass between closing and announcing, and what happened to the 2026 launch date?
  • Which on-pack claim can a brand defend in the US and the EU before human data exist?

Sources and reporting

  1. Companies House: Zya Enzymes Ltd (11416767) filing history, SH01 returns of allotment filed 16 January 2026 and director appointments filed 23 and 25 January 2026 (primary)
  2. AgFunderNews: Exclusive: Zya raises $15m Series A to rethink sugar reduction, no reformulation required, 16 November 2026 (secondary)
  3. Soapbox: Zya lands a £12m Series A round led by Astanor, 16 November 2026 (announcement with company and investor quotes)
  4. Startupmag: Zya raises £11.3m from Astanor and Red Bull Ventures, 16 November 2026 (secondary)
  5. WIRED: A New Startup Wants to Turn the Sugar You Eat Into Fiber, 23 February 2024 (secondary)
  6. Toxicology Reports 17:102321: Toxicological evaluation of a recombinant inulosucrase (Convero®), July 2026 (peer-reviewed, company co-authored)
  7. WO2022096864A1: Use of fructosyltransferase, priority 3 November 2020 (patent application)

Reporting note: Desk report checked against Companies House filings and six published sources, all read on 17 November 2026. FoodEdge found no release on Zya's own website. The GBP 11.5M figure matches FoodEdge's sum of the Series A-2 cash allotments in the SH01 returns (about GBP 11.48M at GBP 0.632116 a share); the Series A-1 total of about GBP 2.2M is also a FoodEdge sum. Startupmag (GBP 11.3M) and Soapbox (GBP 12M) give different totals; FoodEdge follows the filings. The 30% conversion, pipeline and scale-up statements are company claims. Co-founder Niels Leckie appears as Niels Wicke on the patent and earlier filings. Currency: ECB euro reference rate of 16 November 2026, €1 = GBP 0.83450. FoodEdge has not spoken to Zya or its investors.

AI tools supported source research and drafting during the editorial process.

DiscussionOpenClose

More to explore

All publications